


Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1

Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Features

- **Design:** Open-label, randomized, phase 3 trial using fixed-dose combination of ledipasvir-sofosbuvir +/- ribavirin for 12 or 24 weeks in treatment-naïve patients with GT1 HCV
- **Setting:** 99 sites in United States and Europe
- **Entry Criteria**
 - Chronic HCV genotype 1 (n = 865)
 - 18 years or older
 - No prior HCV treatment
 - Patients with compensated cirrhosis accepted (up to 20% of patients)
- **Primary End Point:** SVR12

Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Study Design



Abbreviations: LDV-SOF=ledipasvir-sofosbuvir; RBV=ribavirin

Drug Dosing: Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily or Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg


Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Baseline Characteristics

Baseline Characteristic	12-Week Treatment		24-Week Treatment	
	LDV-SOF (n = 214)	LDV-SOF + RBV (n = 217)	LDV-SOF (n = 217)	LDV-SOF + RBV (n = 217)
Mean age, y (range)	52 (18–75)	52 (18–78)	53 (22–80)	53 (24–77)
BMI, kg/m ² mean (range)	27 (18–41)	27 (18–42)	27 (18–48)	26 (18–48)
Male sex, n (%)	127 (59)	128 (59)	139 (64)	119 (55)
Race				
White, n (%)	187 (87)	188 (87)	177 (82)	183 (84)
Black, n (%)	24 (11)	26 (12)	32 (15)	26 (12)
Hispanic ethnic group, n (%)	26 (12)	20 (9)	29 (13)	26 (12)
HCV Genotype				
1a, n (%)	144 (67)	148 (68)	146 (67)	143 (66)
1b, n (%)	66 (31)	68 (31)	68 (31)	71 (33)
IL28B non CC, n (%)	175 (76)	141 (65)	165 (76)	144 (66)
Cirrhosis, n (%)	34 (16)	33 (15)	33 (15)	36 (17)
HCV RNA, log ₁₀ IU/mL (mean)	6.4	6.4	6.3	6.3

Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Results

ION-1: SVR 12* by Treatment Duration and Regimen




Abbreviations: LDV-SOF=Ledipasvir-sofosbuvir; RBV=ribavirin

* Primary end-point by intention-to-treat analysis

Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Results


ION-1: SVR12 by Treatment Regimen and Liver Disease



Note: subgroup results do not include patients who withdrew consent or were lost to follow-up

Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Results for Ledipasvir-Sofosbuvir

ION-1: SVR12 by Treatment Duration and Liver Disease



Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Resistance Data

- **NS5A resistant variants**

- Baseline resistance in 140 (16%) of 861 patients tested
- SVR12 in 135 (96%) of 140 patients with NS5A resistance
- 2 of the 3 patients with virologic failure had baseline NS5A resistance

Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1 ION-1 Study: Conclusions

Conclusions: “Once-daily ledipasvir–sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.”

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



The contents in this presentation are those of the author(s) and do not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.